Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors

James P. Thomas, Rhoda Z. Arzoomanian, Dona Alberti, Rebecca Marnocha, Fred Lee, Andreas Friedl, Kendra Tutsch, Amy Dresen, Peter Geiger, James Pluda, William Fogler, Joan H. Schiller, George Wilding

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Purpose: Endostatin is the first endogenous angiogenesis inhibitor to enter clinical trials. Laboratory investigations with endostatin have indicated broad antitumor activity coupled with remarkably low toxicity. A phase I trial of recombinant human endostatin was designed to evaluate toxicity and explore biologic effectiveness in patients with refractory solid tumors. Patients and Methods: Endostatin was administered as a 1-hour intravenous infusion given daily for a 28-day cycle. A starting dose of 30 mg/m2 was explored with subsequent dose escalations of 60, 100, 150, 225, and 300 mg/m2. Assessment of serum pharmacokinetics was performed on all 21 patients. Western blot assay and mass spectroscopy were employed to evaluate endostatin metabolism. Circulating levels of endogenous proangiogenic growth factors were examined. Tumor and tumor blood supply were imaged by dynamic computed tomography (CT), magnetic resonance imaging, ultrasound, and positron emission tomography. Results: Endostatin given on this schedule was essentially free of significant drug-related toxicity. Two transient episodes of grade 1 rash were observed. No clinical responses were observed. Endostatin pharmacokinetics were linear with dose, and serum concentrations were achieved that are associated with antitumor activity in preclinical models. No aggregate effect on circulating proangiogenic growth factors were seen, although several patients exhibited persistent declines in vascular endothelial growth factor levels while enrolled in the study. A few patients demonstrated changes in their dynamic CT scans suggestive of a decline in microvessel density, although overall, no consistent effect of endostatin on tumor vasculature was seen. Conclusion: Endostatin given daily as a 1-hour intravenous infusion was well tolerated without dose-limiting toxicity at doses up to 300 mg/m2.

Original languageEnglish (US)
Pages (from-to)223-231
Number of pages9
JournalJournal of Clinical Oncology
Volume21
Issue number2
DOIs
StatePublished - Jan 15 2003

Fingerprint

Endostatins
Pharmacokinetics
Neoplasms
Intravenous Infusions
Intercellular Signaling Peptides and Proteins
Tomography
Angiogenesis Inhibitors
Microvessels
Exanthema
Drug-Related Side Effects and Adverse Reactions
Serum
Positron-Emission Tomography
Vascular Endothelial Growth Factor A
Mass Spectrometry
Appointments and Schedules
Western Blotting
Magnetic Resonance Imaging
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thomas, J. P., Arzoomanian, R. Z., Alberti, D., Marnocha, R., Lee, F., Friedl, A., ... Wilding, G. (2003). Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. Journal of Clinical Oncology, 21(2), 223-231. https://doi.org/10.1200/JCO.2003.12.120

Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. / Thomas, James P.; Arzoomanian, Rhoda Z.; Alberti, Dona; Marnocha, Rebecca; Lee, Fred; Friedl, Andreas; Tutsch, Kendra; Dresen, Amy; Geiger, Peter; Pluda, James; Fogler, William; Schiller, Joan H.; Wilding, George.

In: Journal of Clinical Oncology, Vol. 21, No. 2, 15.01.2003, p. 223-231.

Research output: Contribution to journalArticle

Thomas, JP, Arzoomanian, RZ, Alberti, D, Marnocha, R, Lee, F, Friedl, A, Tutsch, K, Dresen, A, Geiger, P, Pluda, J, Fogler, W, Schiller, JH & Wilding, G 2003, 'Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors', Journal of Clinical Oncology, vol. 21, no. 2, pp. 223-231. https://doi.org/10.1200/JCO.2003.12.120
Thomas, James P. ; Arzoomanian, Rhoda Z. ; Alberti, Dona ; Marnocha, Rebecca ; Lee, Fred ; Friedl, Andreas ; Tutsch, Kendra ; Dresen, Amy ; Geiger, Peter ; Pluda, James ; Fogler, William ; Schiller, Joan H. ; Wilding, George. / Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 2. pp. 223-231.
@article{20653e5a0255457fac29e614bc0ac8b2,
title = "Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors",
abstract = "Purpose: Endostatin is the first endogenous angiogenesis inhibitor to enter clinical trials. Laboratory investigations with endostatin have indicated broad antitumor activity coupled with remarkably low toxicity. A phase I trial of recombinant human endostatin was designed to evaluate toxicity and explore biologic effectiveness in patients with refractory solid tumors. Patients and Methods: Endostatin was administered as a 1-hour intravenous infusion given daily for a 28-day cycle. A starting dose of 30 mg/m2 was explored with subsequent dose escalations of 60, 100, 150, 225, and 300 mg/m2. Assessment of serum pharmacokinetics was performed on all 21 patients. Western blot assay and mass spectroscopy were employed to evaluate endostatin metabolism. Circulating levels of endogenous proangiogenic growth factors were examined. Tumor and tumor blood supply were imaged by dynamic computed tomography (CT), magnetic resonance imaging, ultrasound, and positron emission tomography. Results: Endostatin given on this schedule was essentially free of significant drug-related toxicity. Two transient episodes of grade 1 rash were observed. No clinical responses were observed. Endostatin pharmacokinetics were linear with dose, and serum concentrations were achieved that are associated with antitumor activity in preclinical models. No aggregate effect on circulating proangiogenic growth factors were seen, although several patients exhibited persistent declines in vascular endothelial growth factor levels while enrolled in the study. A few patients demonstrated changes in their dynamic CT scans suggestive of a decline in microvessel density, although overall, no consistent effect of endostatin on tumor vasculature was seen. Conclusion: Endostatin given daily as a 1-hour intravenous infusion was well tolerated without dose-limiting toxicity at doses up to 300 mg/m2.",
author = "Thomas, {James P.} and Arzoomanian, {Rhoda Z.} and Dona Alberti and Rebecca Marnocha and Fred Lee and Andreas Friedl and Kendra Tutsch and Amy Dresen and Peter Geiger and James Pluda and William Fogler and Schiller, {Joan H.} and George Wilding",
year = "2003",
month = "1",
day = "15",
doi = "10.1200/JCO.2003.12.120",
language = "English (US)",
volume = "21",
pages = "223--231",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors

AU - Thomas, James P.

AU - Arzoomanian, Rhoda Z.

AU - Alberti, Dona

AU - Marnocha, Rebecca

AU - Lee, Fred

AU - Friedl, Andreas

AU - Tutsch, Kendra

AU - Dresen, Amy

AU - Geiger, Peter

AU - Pluda, James

AU - Fogler, William

AU - Schiller, Joan H.

AU - Wilding, George

PY - 2003/1/15

Y1 - 2003/1/15

N2 - Purpose: Endostatin is the first endogenous angiogenesis inhibitor to enter clinical trials. Laboratory investigations with endostatin have indicated broad antitumor activity coupled with remarkably low toxicity. A phase I trial of recombinant human endostatin was designed to evaluate toxicity and explore biologic effectiveness in patients with refractory solid tumors. Patients and Methods: Endostatin was administered as a 1-hour intravenous infusion given daily for a 28-day cycle. A starting dose of 30 mg/m2 was explored with subsequent dose escalations of 60, 100, 150, 225, and 300 mg/m2. Assessment of serum pharmacokinetics was performed on all 21 patients. Western blot assay and mass spectroscopy were employed to evaluate endostatin metabolism. Circulating levels of endogenous proangiogenic growth factors were examined. Tumor and tumor blood supply were imaged by dynamic computed tomography (CT), magnetic resonance imaging, ultrasound, and positron emission tomography. Results: Endostatin given on this schedule was essentially free of significant drug-related toxicity. Two transient episodes of grade 1 rash were observed. No clinical responses were observed. Endostatin pharmacokinetics were linear with dose, and serum concentrations were achieved that are associated with antitumor activity in preclinical models. No aggregate effect on circulating proangiogenic growth factors were seen, although several patients exhibited persistent declines in vascular endothelial growth factor levels while enrolled in the study. A few patients demonstrated changes in their dynamic CT scans suggestive of a decline in microvessel density, although overall, no consistent effect of endostatin on tumor vasculature was seen. Conclusion: Endostatin given daily as a 1-hour intravenous infusion was well tolerated without dose-limiting toxicity at doses up to 300 mg/m2.

AB - Purpose: Endostatin is the first endogenous angiogenesis inhibitor to enter clinical trials. Laboratory investigations with endostatin have indicated broad antitumor activity coupled with remarkably low toxicity. A phase I trial of recombinant human endostatin was designed to evaluate toxicity and explore biologic effectiveness in patients with refractory solid tumors. Patients and Methods: Endostatin was administered as a 1-hour intravenous infusion given daily for a 28-day cycle. A starting dose of 30 mg/m2 was explored with subsequent dose escalations of 60, 100, 150, 225, and 300 mg/m2. Assessment of serum pharmacokinetics was performed on all 21 patients. Western blot assay and mass spectroscopy were employed to evaluate endostatin metabolism. Circulating levels of endogenous proangiogenic growth factors were examined. Tumor and tumor blood supply were imaged by dynamic computed tomography (CT), magnetic resonance imaging, ultrasound, and positron emission tomography. Results: Endostatin given on this schedule was essentially free of significant drug-related toxicity. Two transient episodes of grade 1 rash were observed. No clinical responses were observed. Endostatin pharmacokinetics were linear with dose, and serum concentrations were achieved that are associated with antitumor activity in preclinical models. No aggregate effect on circulating proangiogenic growth factors were seen, although several patients exhibited persistent declines in vascular endothelial growth factor levels while enrolled in the study. A few patients demonstrated changes in their dynamic CT scans suggestive of a decline in microvessel density, although overall, no consistent effect of endostatin on tumor vasculature was seen. Conclusion: Endostatin given daily as a 1-hour intravenous infusion was well tolerated without dose-limiting toxicity at doses up to 300 mg/m2.

UR - http://www.scopus.com/inward/record.url?scp=0037440123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037440123&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.12.120

DO - 10.1200/JCO.2003.12.120

M3 - Article

C2 - 12525513

AN - SCOPUS:0037440123

VL - 21

SP - 223

EP - 231

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -